Clinical trial · Interventional
Camrelizumab Combined With Famitinib Malate and Chemotherapy for Treatment of Recurrent/ Metastatic Cervical Cancer
A Multi-Center Phase II Clinical Study of Camrelizumab Combined With Famitinib Malate and Platinum-based Chemotherapy in the Treatment of Recurrent/Metastatic Cervical Cancer
NCT07627620CI-TRIAL-00113633not yet recruitingPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is an open-label, multi-center Phase II clinical study, aimed to evaluate the efficacy and safety of camrelizumab combined with famitinib malate and platinum-based chemotherapy in the treatment of recurrent/metastatic cervical cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cervical Cancer | Malignant Cervical Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Camrelizumab | Drug | Camrelizumab | ALIAS |
| Chemotherapy | Drug | Chemotherapy | ALIAS |
| Famitinib Malate | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Camrelizumab combined with famitinib malate and chemotherapy
- interventionNames
- Drug: Camrelizumab
- Drug: Famitinib Malate
- Drug: Chemotherapy
Primary outcomes (1)
- measure
- Objective response rate (ORR)
- timeFrame
- up to 2 years
- description
- Objective Response Rate defined as the percentage of participants who have a complete response or a partial response (PR) per RECIST 1.1.
Secondary outcomes (6)
- measure
- Disease control rate (DCR)
- timeFrame
- up to 2 years
- description
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. Female aged 18-75 years. 2. Histopathologically confirmed recurrent/metastatic cervical squamous cell carcinoma, adenocarcinoma or adenosquamous cell carcinoma that cannot be radically treated by surgery, radiotherapy or chemoradiotherapy. 3. No prior systemic anti-cancer therapy for recurrent/metastatic disease. 4. According to RECIST v1.1 criteria, the patient must have at least one measurable lesion. 5. Able to normally swallow drug tablets 6. Has adequate organ function. 7. Willing to participate and able to comply with research programme requirements. 8. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. 9. Estimated life expectancy of more than 3 months. Exclusion Criteria: 1. Has any malignancy \<5 years prior to study entry. 2. Known to have brain or meningeal metastasis. 3. Known to have autoimmune disease. 4. Received live vaccinations 4 weeks before randomization or during the study period. 5. Known allergies and contraindications to the investigational drug or any of its components.
References
Publications (0)
Data not yet available
No reference posted for this study.